{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T04:02:20Z","timestamp":1747368140112,"version":"3.40.5"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Measurable residual disease (MRD) in B\u2010cell precursor acute lymphoblastic leukemia (BCP\u2010ALL) following anti\u2010CD19 targeted therapies requires specific strategies to identify residual blast cells due to loss or reduced CD19 expression that makes it inconsistent as a primitive marker for B\u2010cell gating.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Due to the increased access of BCP\u2010ALL patients to therapies with CD3\/CD19 bispecific T\u2010cell engagers (BiTe) and CD19\u2010targeted chimeric antigen receptor T\u2010Cell (CAR\u2010T), it is essential that flow cytometry laboratories are prepared to evaluate therapeutic responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and Methods<\/jats:title><jats:p>Here, validated strategies for MRD detection in the context of anti\u2010CD19 therapies are described, accessible to flow cytometry laboratories according to their different facilities. The paper includes an 8\u2010color flow cytometry (FC) strategy for BCP\u2010ALL MRD based on alternative gating without the use of additional markers (Euroflow protocol), as well as other strategies using alternative markers to CD19, comprising 2 protocols using 8 colors, one using 10 colors and another 14 colors\/15 markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Different strategies are needed to detect MRD without using CD19 for B\u2010cell population gating after CD19\u2010targeted therapies. However, it is essential that validated protocols are used according to the available resources to ensure reliable results for clinical decision\u2010making.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijlh.14448","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T08:50:44Z","timestamp":1740559844000},"page":"398-406","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["How I Investigate Measurable Residual Disease in B\u2010Cell Precursor Acute Lymphoblastic Leukemia After Therapy With Bi\u2010Specific Monoclonal Antibodies and <scp>19CAR<\/scp>\u2010T Cells"],"prefix":"10.1111","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-9696","authenticated-orcid":false,"given":"Maura Rosane","family":"Valerio Ikoma\u2010Colturato","sequence":"first","affiliation":[{"name":"Hospital Amaral Carvalho  Ja\u00fa Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe Magalh\u00e3es","family":"Furtado","sequence":"additional","affiliation":[{"name":"Hospital da Crian\u00e7a de Bras\u00edlia Jos\u00e9 Alencar  Bras\u00edlia Brazil"},{"name":"Sabin Medicina Diagn\u00f3stica  Bras\u00edlia Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elen","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Instituto de Puericultura e Pediatria e Martag\u00e3o Gesteira (IPPMG\/UFRJ)  Rio de Janeiro Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Gevert","sequence":"additional","affiliation":[{"name":"Hospital Pequeno Pr\u00edncipe  Curitiba Brazil"},{"name":"Hospital Erasto Gaertner  Curitiba Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberia","family":"Mendon\u00e7a","sequence":"additional","affiliation":[{"name":"Hospital da Crian\u00e7a de Bras\u00edlia Jos\u00e9 Alencar  Bras\u00edlia Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The Brazilian Society of Bone Marrow and Cell Therapy (SBTMO) MRD Working Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023568"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.12.009"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI87366"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1165870"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25094881"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21482"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22088"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17992"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122544"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bulcan.2021.08.001"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.07.002"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.122"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14685"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18499"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.44"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21228"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17382"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22159"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22113"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1515\/dx\u20102018\u20100051"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000676"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22046"},{"key":"e_1_2_13_25_1","unstructured":"EuroFlow \u201cEuroFlow Guidelines for BM Sample Collection and Transport for MM MRD Measurements Version 1.0\u20133 April 2017 \u201dhttps:\/\/euroflow.org\/protocols\/."},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21854"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.22120"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.5935\/1676-2444.20150061"},{"key":"e_1_2_13_29_1","unstructured":"EuroFlow \u201cEuroFlow SOP for bulk lysis in MRD panels Version 1.3\u201325 June 2018 \u201dhttps:\/\/www.euroflow.org\/protocols."},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201007\u2010726307"},{"issue":"3","key":"e_1_2_13_31_1","first-page":"307","article-title":"Use of an Automated Hematology Analyzer and Flow Cytometry to Assess Bone Marrow Cellularity and Differential Cell Count","volume":"34","author":"Kim M.","year":"2004","journal-title":"Annals of Clinical and Laboratory Science"},{"key":"e_1_2_13_32_1","unstructured":"EuroFlow \u201cEuroFlow SOP for Sample Preparation Version 1.7\u20131 November 2023 \u201dhttps:\/\/www.euroflow.org\/protocols."},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2016.12.006"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2018.03.005"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201009\u2010801498"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.09.1074"},{"key":"e_1_2_13_37_1","doi-asserted-by":"crossref","unstructured":"M. N.Dworzak G.Fritsch G.Fr\u00f6 D.Printz andH.Gadner \u201cFour\u2010Color Flow Cytometric Investigation of Terminal Deoxynucleotidyl Transferase\u2010Positive Lymphoid Precursors in Pediatric Bone Marrow: CD79a Expression Precedes CD19 in Early B\u2010Cell Ontogeny \u201dhttps:\/\/ashpublications.org\/blood\/article\u2010pdf\/92\/9\/3203\/1648572\/3203.pdf.","DOI":"10.1182\/blood.V92.9.3203.421k34_3203_3209"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14215445"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25953"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018018093"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.14448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T06:07:34Z","timestamp":1747289254000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.14448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/ijlh.14448"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.14448","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"type":"print","value":"1751-5521"},{"type":"electronic","value":"1751-553X"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"2024-09-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}